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Even at a very early stage in paediatric HIV infection, 
polymerase chain reaction (PCR) has been shown 
to be highly sensitive and specific.[1] However, when 
the clinical picture is inconsistent with laboratory 
results, additional investigation is warranted. Several 
published studies have reported concerns about the ability of PCR 
tests to detect all current subtypes as a result of HIV-1 genetic 
diversity.[2-6] These concerns include the COBAS AmpliPrep/COBAS 
Taqman (CAP/CTM) HIV-1 Qual Test (Roche Molecular Systems, 
Branchburg, NJ, USA) which, until recently, was widely used in 
South Africa (SA) and is reported to have 99.7% sensitivity and 100% 
specificity.[7] We describe a case of a false-negative HIV PCR using 
this assay to detect vertically transmitted HIV infection in an SA 
child. Failure to recognise HIV infection at an early stage severely 
compromised the health of this child. Gag-specific sequencing of the 
virus in both mother and child was carried out to explore the reason 
for lack of detection by the qualitative PCR assay.
Case description
In January 2014 a critically ill 15-month-old boy was transferred to 
Red Cross War Memorial Children’s Hospital, Cape Town, SA from a 
secondary hospital. He had acute gastroenteritis with hypovolaemic 
shock, a lower respiratory tract infection, septicaemia, pyogenic 
myositis of his left thigh, and subungual abscesses of both thumbs 
caused by methicillin-sensitive Staphylococcus aureus. He responded 
to cloxacillin, fluid and electrolyte replacement and nutritional 
rehabilitation. Of note in his background medical history was that 
his mother was diagnosed serologically with HIV infection 5 months 
into her pregnancy. Dual zidovudine and nevirapine prophylaxis 
was administered antenatally and during labour, and postnatally the 
child received 4 weeks of zidovudine prophylaxis. He was breastfed 
until 4 months of age. Between the ages of 6 and 9 months he was 
hospitalised on three occasions for gastroenteritis and respiratory 
tract infection (two admissions) and tuberculosis (one admission).
Table 1 shows the HIV-related test history of the child and his 
mother – alternative PCR assays were initiated at the time of the 
child’s correct diagnosis and performed retrospectively on previous 
archived samples. The earliest qualitative HIV PCR test using the 
routinely available method (COBAS AmpliPrep/COBAS Taqman 
(CAP/CTM) HIV-1 Qual Test version 1) at 6 weeks was negative. 
Repeat PCR tests during subsequent admissions were also negative. 
A rapid antibody test at 15 months during admission to our hospital 
was positive. Because of the clinical suspicion of HIV infection, an 
HIV viral load test (Abbott RealTime HIV-1, Abbott Molecular Inc., 
Des Plaines, IL, USA) was performed, which documented 1 562 169 HIV 
copies/mL (log10 6.19). Alternative PCR assays[8,9] using different primer 
sets also detected HIV proviral DNA. The child’s CD4 count was 
markedly reduced at 64 cells/µL (3.86%). He was commenced on 
abacavir, lamivudine, lopinavir/ritonavir and co-trimoxazole, made 
remarkable progress and was discharged after 14 days.
HIV gag-specific PCR was performed for diagnostic purposes and 
to investigate viral genotypic characteristics, which could inform 
reasons for lack of detection by the CAP/CTM assay (methodology 
available on request). Samples taken from both mother and child 
around the time of diagnosis, as well as archived samples from the 
child taken at 6 and 7 months of age, were all gag PCR-positive (Table 1). 
Amplification of partial gag (160 base pairs)[8] confirmed the presence 
of HIV in the child. Sequence analyses of full-length gag[9] amplified 
from infant and maternal samples confirmed that both were infected 
with HIV-1 subtype C, the predominant subtype in SA, with no 
evidence of intersubtype recombination (Fig. 1A).
We analysed the most conserved region of gag, the p24 capsid 
region, which is more likely to contain primer/probe target regions. 
The sequence of an HIV subtype C infectious molecular clone (IMC) 
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Polymerase chain reaction (PCR) testing is the gold standard for determining the HIV status in children <18 months of age. However, when clinical 
manifestations are not consistent with laboratory results, additional investigation is required. We report a 15-month-old HIV-exposed boy referred 
to our hospital after he had been admitted several times for infectious diseases. A rapid antibody test on the child was positive, while routine 
diagnostic HIV PCRs using the Roche COBAS Ampliprep/COBAS TaqMan HIV Qual Test were negative at 6 weeks, 6 months, 7 months and 
15 months. In addition, the same PCR test performed on the HIV-infected mother was also negative. Alternative PCR and viral load assays using 
different primer sets detected HIV RNA or proviral DNA in both child and mother. Gag sequences from the child and his mother classified both 
infections as HIV-1 subtype C, with very rare mutations that may have resulted in PCR assay primer/probe mismatch. Consequently, the child was 
commenced on antiretroviral therapy and made a remarkable recovery. These findings indicate that more reliable PCR assays capable of detecting 
a wide range of HIV subtypes are desirable to circumvent the clinical problems created by false-negative PCR results.
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Table 1. HIV-related test results
Sample Age Test method Result
Child
C1 6 weeks CAP/CTM Qual PCR* Negative
C2 6 months CAP/CTM Qual PCR* Negative
Full-length gag PCR[9] Positive
C3 7 months CAP/CTM Qual PCR* Negative
Full-length gag PCR[9] Positive
C4 15 months Determine HIV-1/2 antibody† Reactive
C5 15 months Enzygnost Anti-HIV 1/2 plus ELISA‡ Reactive
C6 15 months PanLeucogating CD4 count (Beckman Coulter)[10] 64 cells/μL (3.86%)
CAP/CTM Qual PCR* Negative
Partial gag PCR[8] Positive
C7 15 months Abbott RealTime HIV-1 viral load§ 1 562 169 copies/mL (log10 6.19)
C8, C9, C10 15 months CAP/CTM Qual PCR* Negative
C10 15 months CAP/CTM Qual PCR version 2¶ Positive
Full-length gag PCR[9] Positive
Mother
M1 19 years Determine HIV-1/2 antibody† Reactive
M2 19 years ARCHITECT HIV Ag/Ab Combo ELISA|| Reactive
Enzygnost Anti-HIV 1/2 Plus ELISA‡ Reactive
CAP/CTM Qual PCR* Negative
Full-length gag PCR[9] Positive
Abbott RealTime HIV-1 viral load§ 51 977 copies /mL (log10 4.72)
*COBAS AmpliPrep/COBAS Taqman HIV-1 Qual Test (Roche Molecular Systems, Branchburg, NJ, USA).
†Determine HIV-1/2 (Alere Medical, Chiba, Japan).
‡Enzygnost Anti-HIV 1/2 Plus (Siemens, Marburg, Germany).
§Abbott RealTime HIV-1 (Abbott Molecular Inc, Des Plaines, Ill., USA).
¶COBAS Ampliprep/ COBAS Taqman HIV-1 Qualitative test, V2.0 (Roche Molecular Systems, Branchburg, NJ, USA).
||ARCHITECT HIV Ag/Ab Combo (Abbott Laboratories, Wiesbaden, Germany).
Fig. 1. Subtyping and identification of rare mutations in the mother and infant samples. (A) A neighbour-joining phylogenetic tree of global subtype reference and 
SA subtype C gag sequences (www.hiv.lanl.gov). Both the infant’s sample C6 (indicated by a closed circle) and the mother’s sample M2 (indicated by an open circle) 
cluster with subtype C sequences. Scale bar = 0.02. (B) Rare mutations and a rare pairing of mutations in gag p24 sequences from samples C6, M2 and the subtype 
C IMC plasmid pBR246-F10, when compared with a consensus subtype C sequence and database subtype C sequences from the CAPRISA 002 cohort (previously 
detected by the COBAS Amplicor 1.5/Taqman HIV-1 test),[11,12] are illustrated in a highlighter nucleotide mismatch plot (www.hiv.lanl.gov). Rare mutations shared by 
the infant and mother are indicated by clear grey bars and the rare mutation pair shared by the infant, mother and IMC are indicated by shaded grey bars. Nucleotide 
mismatches relative to the consensus are shown as coloured blocks. Nucleic acid numbering relative to consensus C gag p24 is indicated.
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(pBR246F-10, provided by B Hahn), previously identified in our lab 
as failing to amplify on the CAP/CTM assay, was included in the 
analysis. Three individual nucleotide mutations (A202C, G204T 
and C647T, shared by the infant and mother sequences) and one 
pair of mutations (G657A together with T672C/A, shared by the 
mother, infant and IMC sequences) were identified as rare, based on their 
frequency within 530 database SA subtype C sequences (www.hiv.lanl.gov) 
(present in <1% of subtype C sequences) (Fig. 1B).
Because of the proprietary nature of the primers and probes 
of the Roche CAP/CTM HIV Qual assay, we were unable to 
obtain their sequences to compare with the primer/probe binding 
region sequences of the mother and infant viruses. However, Roche 
Diagnostics was able to confirm that the sequence of both the 
IMC and the mother/infant virus contained critical primer/probe 
mismatches that may prevent detection using the first version of 
the CAP/CTM HIV-1 Qual assay. They confirmed that the newer 
version of the CAP/CTM assay, released late in 2013, would detect 
the virus, which was confirmed by another laboratory evaluating the 
performance of version 2 of the assay.
Discussion
Bøgh et al.[2] reported that the Amplicor HIV-1 DNA PCR test 
(Roche Molecular Systems, Branchburg, NJ, USA) did not detect 
all subtypes with equivalent sensitivity and that 10% of the non-
subtype B samples tested negative. Kline et al.[3] reported a false-
negative Amplicor HIV-1 DNA PCR in an infant with subtype C 
HIV infection. Other studies have similarly shown that version 1.0 of 
the Roche COBAS Ampliprep/COBAS Taqman (CAP/CTM, Roche 
Molecular Systems, Branchburg, NJ, USA) HIV-1 viral load assay 
may rarely under-quantify or fail to detect non-B subtypes.[4-6] In a 
report[13] in which the majority of women were African and likely to 
have non-B subtypes of HIV-1, nearly a quarter of the 108 samples 
collected from pregnant women gave rise to false-negative results 
in the routine assay (Roche Amplicor version 1.0). In this setting, if 
additional tests had not been conducted, misdiagnosis in infants may 
have occurred.
This report describes a case of a false-negative qualitative PCR in 
a young child and his mother, both of whom have HIV-1 subtype C 
infection, confirmed by positive antibody and alternative DNA and 
RNA PCR assays.
It is not possible to determine the exact timing of the child’s 
infection; however, failure of the routine PCR to detect HIV despite 
repeated attempts represents a missed opportunity for early diagnosis 
and resulted in multiple admissions and severe illness, requiring 
intensive care. This emphasises the need for a high index of suspicion 
in an HIV-exposed infant with clinical evidence of recurrent 
infections and failure to thrive.
To reduce the risk of false-negative PCR tests, some guidelines 
have suggested molecular testing of a maternal sample as part of 
routine paediatric diagnosis.[11] In cases where maternal HIV DNA 
cannot be detected on the routine assay, an alternative assay able to 
detect the maternal virus can be used to test the infant.[11] Testing 
samples with a qualitative PCR with a parallel quantitative assay 
has also been suggested.[11] However, in endemic settings with a 
high prevalence of HIV, implementation of these policies may pose 
logistic challenges in terms of cost and feasibility, negating their use 
in routine practice.
In this case report, the false-negative CAP/CTM result could likely 
be explained by primer or probe mismatches. We identified three rare 
mutations and a rare pairing of mutations in both the mother and 
infant sequences, which could have accounted for lack of detection. 
However, this could not be confirmed in the absence of primer/
probe sequence information. Qualitative assays that are more reliable 
in detecting HIV would be the long-term solution to the problem of 
false-negative PCR tests.[2,3]
Additional HIV diagnostic testing is required when there are 
doubts about the HIV status of a symptomatic exposed infant. 
Continued surveillance and reporting of cases of HIV non-detection 
are therefore necessary. Upgrading of the amplification tests for better 
detection of all HIV subtypes is also essential. The new version of the 
qualitative CAP/CTM assay (version 2), which targets both the gag 
and LTR regions of the virus, should have an improved sensitivity 
and inclusivity profile.
Conclusion
Opportunities were missed for early diagnosis and treatment of 
HIV in this child. PCR assays that are more reliable in detecting a 
wide range of HIV subtypes and variants are desirable to prevent 
the problem of false-negative PCR tests. Clinicians should consider 
a negative PCR result to possibly be false in cases where the clinical 
picture does not match the laboratory report.
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